SCYNEXIS, Inc (SCYX)

Etorro trading 970x250
SCYNEXIS, Inc (SCYX) Logo

About SCYNEXIS, Inc

SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase II clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey. Address: 1 Evertrust Plaza, Jersey City, NJ, United States, 07302-6548

SCYNEXIS, Inc News and around…

Latest news about SCYNEXIS, Inc (SCYX) common stock and company :

SCYNEXIS to Host Ibrexafungerp Hospital Pipeline Update Call and KOL Webcast for Investors on December 6
29 Nov, 2021 Yahoo! Finance

JERSEY CITY, N.J., Nov. 29, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will host a hospital pipeline update for its novel antifungal, ibrexafungerp, during a webcast on Monday, December 6, at 10 a.m. ET. The webcast event will feature a presentation from Martin Hoenigl, M.D., Associate Professor, FECMM, Division of Infectious Disea

SCYNEXIS Pivotal Phase 3 VANISH-306 Trial Results Published in the International Journal of Obstetrics and Gynaecology (BJOG) Demonstrate Statistical Superiority of BREXAFEMME® (Ibrexafungerp Tablets) Over Placebo for Vaginal Yeast Infection
23 Nov, 2021 Yahoo! Finance

Patients receiving one-day treatment with oral ibrexafungerp had significantly higher rates of clinical cure, mycological eradication, and clinical improvement at Day-10 compared to placebo-treated patients. Ibrexafungerp demonstrated sustained clinical effect at Day-25 follow-up with 73.9% of treated patients achieving a complete resolution of signs and symptoms.The Phase 3 VANISH clinical trial program (VANISH-303 and VANISH-306) supported the approval of BREXAFEMME by the U.S. Food and Drug A

52 Biggest Movers From Friday
22 Nov, 2021 FinancialContent

Gainers Greenland Technologies Holding Corporation (NASDAQ: GTEC) shares surged 90.2% to close at $9.89 on Friday. Greenland ...

12 Health Care Stocks Moving In Friday's Intraday Session
19 Nov, 2021 FinancialContent

Gainers SCYNEXIS (NASDAQ:SCYX) stock rose 15.69% to $7.15 during Friday's regular session. As of 12:30 EST, this ...

33 Stocks Moving In Friday's Mid-Day Session
19 Nov, 2021 FinancialContent

Gainers Greenland Technologies Holding Corporation (NASDAQ: GTEC) shares jumped 75.4% to $9.17. Greenland Technologies ...

Michael Burry dumped just about everything in Q3 to guard against the 'mother of all crashes' — but he did purchase 3 interesting new holdings
18 Nov, 2021 Yahoo! Finance

'The Big Short' guy is bearish. But not on this trio of plays.

70 Biggest Movers From Yesterday
16 Nov, 2021 FinancialContent

Gainers Casper Sleep Inc. (NYSE: CSPR) shares jumped 88.5% to close at $6.69 on Monday after the company agreed to be ...

Michael Burry Covered His Short on TSLA, For Now
15 Nov, 2021 FinancialContent
12 Health Care Stocks Moving In Monday's Intraday Session
15 Nov, 2021 FinancialContent

Gainers Tricida (NASDAQ:TCDA) shares rose 15.2% to $6.29 during Monday's regular session. Tricida's stock is trading at a volume of ...

Scynexis (SCYX) Reports Q3 Loss, Tops Revenue Estimates
10 Nov, 2021 Yahoo! Finance

Scynexis (SCYX) delivered earnings and revenue surprises of 92.41% and 3.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

SCYNEXIS Reports Third Quarter 2021 Financial Results and Provides Corporate Update
10 Nov, 2021 Yahoo! Finance

BREXAFEMME® (ibrexafungerp tablets) net sales of $0.5 million generated since August, with IQVIA reporting 1,006 prescriptions in partial Q3; momentum is continuing into Q4 with an additional 1,100 prescriptions reported in October.BREXAFEMME is now covered by commercial insurance plans representing more than 30% of commercially insured lives, exceeding internal expectations.Intravenous (IV) ibrexafungerp is ready to advance to the next stage of clinical development following successful Phase 1

SCYNEXIS Announces Successful Completion of Phase 1 Trial Evaluating Intravenous (IV) Formulation of Ibrexafungerp
09 Nov, 2021 Yahoo! Finance

Safety and tolerability of new liposomal IV formulation confirmed to reach target exposure in single ascending dose (SAD) and multiple ascending dose (MAD) studyJERSEY CITY, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the successful completion of a Phase 1 clinical study to evaluate the safety, tolerability and pharmacokineti

SCYNEXIS to Provide a Corporate Update and Report Third Quarter 2021 Financial Results on November 10
03 Nov, 2021 Yahoo! Finance

JERSEY CITY, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 10, 2021, to provide a corporate update and discuss the Company’s financial results for the third quarter ended September 30, 2021. Conference call and webcast details: Investors (dom

SCYNEXIS Pivotal Phase 3 VANISH-303 Trial Results Published in Clinical Infectious Diseases Demonstrate Significant Superiority of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection
21 Oct, 2021 Yahoo! Finance

In the Phase 3 VANISH-303 study, ibrexafungerp demonstrated significantly higher rates of clinical cure and infection eradication versus placebo.Post hoc analysis found ibrexafungerp demonstrated consistent efficacy in important patient sub-populations, characterized by race/ethnicity and body mass index.In the Phase 2 DOVE study, ibrexafungerp demonstrated similar efficacy to the current standard of care at the Day 10 visit with sustained efficacy at the Day 25 follow-up visit. JERSEY CITY, N.J

SCYNEXIS to Present Pooled Data Analysis Results Demonstrating Consistent Efficacy and Safety Outcomes Across Two Phase 3 VANISH Clinical Trials of Oral Ibrexafungerp Therapy for Vaginal Yeast Infection at October Medical Conferences
13 Oct, 2021 Yahoo! Finance

JERSEY CITY, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced presentations of a pooled data analysis from its successful VANISH clinical development program during two October medical meetings: the Nurse Practitioners in Women’s Health (NPWH) 24th Annual Premier Women’s Healthcare Conference and the 4th Congress of the Internatio

SCYNEXIS Announces Preclinical Data at the 10th Trends in Medical Mycology Meeting Supporting Potential of Ibrexafungerp to Treat Mucormycosis
11 Oct, 2021 Yahoo! Finance

In vivo data demonstrated response rate for ibrexafungerp similar to current standard of care options for the treatment of mucormycosisCombination of ibrexafungerp with current therapies showed significant enhancement in median survival time and overall survival when compared with standard of care monotherapies JERSEY CITY, N.J., Oct. 11, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and

SCYNEXIS to Present Clinical Data from Ongoing FURI and CARES Studies at the 10th Trends in Medical Mycology Meeting Showing Oral Ibrexafungerp Provides a Favorable Therapeutic Response in Patients with Severe Fungal Infections
07 Oct, 2021 Yahoo! Finance

Pre-clinical data on ibrexafungerp for mucormycosis also will be shared via an oral presentationJERSEY CITY, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced two poster presentations of interim data from its ongoing FURI and CARES studies, evaluating oral ibrexafungerp for the treatment of patients with refractory mucocutaneous an

SCYNEXIS Enters Oversold Territory (SCYX)
04 Oct, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021
30 Sep, 2021 Yahoo! Finance

The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, today announced that 10 of its member companies will present data from their clinical and research programs at IDWeek 2021 taking place virtually from September 29-October 3, 2021. AWG members are presenting a total of 23 poster presentations and 3 oral abstract presentations.

Scynexis Presents Interim Ibrexafungerp Data In Hospital-Based Fungal Infections
29 Sep, 2021 FinancialContent

Scynexis Inc(NASDAQ: SCYX) announced anoral presentation of interim data analysesfrom its ongoing Phase 3 FURI ...

SCYNEXIS Presents Interim Analysis from FURI at Virtual IDWeek 2021 Showing Favorable Therapeutic Response in Severe Hospital-Based Fungal Infections Treated with Oral Ibrexafungerp
29 Sep, 2021 FinancialContent

Subpopulation analysis of 74 patients from ongoing Phase 3 FURI study demonstrated similar efficacy against multiple serious fungal infections

SCYNEXIS Presents Interim Analysis from FURI at Virtual IDWeek 2021 Showing Favorable Therapeutic Response in Severe Hospital-Based Fungal Infections Treated with Oral Ibrexafungerp
29 Sep, 2021 Yahoo! Finance

Subpopulation analysis of 74 patients from ongoing Phase 3 FURI study demonstrated similar efficacy against multiple serious fungal infectionsJERSEY CITY, N.J., Sept. 29, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced an oral presentation of analyses of interim data from its ongoing Phase 3 FURI study showing favorable clinical activity of ora

SCYNEXIS to Present Data on Oral Ibrexafungerp at IDWeek 2021 from Interim Analyses of Phase 3 FURI Clinical Trial Showing Therapeutic Response Rates in Patients with Mucocutaneous and Invasive Fungal
23 Sep, 2021 FinancialContent

Analysis of subpopulations from a total of 74 patients evaluated to date from FURI includes outcomes by disease, bone and joint infections, and mouth and throat candidiasis

SCYNEXIS to Present Data on Oral Ibrexafungerp at IDWeek 2021 from Interim Analyses of Phase 3 FURI Clinical Trial Showing Therapeutic Response Rates in Patients with Mucocutaneous and Invasive Fungal Infections
23 Sep, 2021 Yahoo! Finance

Analysis of subpopulations from a total of 74 patients evaluated to date from FURI includes outcomes by disease, bone and joint infections, and mouth and throat candidiasisJERSEY CITY, N.J., Sept. 23, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced one oral and two poster presentations of interim data from its Phase 3 FURI study, evaluating ora

SCYNEXIS Announces U.S. Availability of BREXAFEMME® (ibrexafungerp tablets), the First New Antifungal Class of Therapy Approved by the U.S. FDA for Vaginal Yeast Infections in More Than 20 Years
22 Sep, 2021 FinancialContent
What Kind Of Shareholders Own SCYNEXIS, Inc. (NASDAQ:SCYX)?
20 Sep, 2021 Yahoo! Finance

A look at the shareholders of SCYNEXIS, Inc. ( NASDAQ:SCYX ) can tell us which group is most powerful. Generally...

SCYNEXIS Announces Hansoh Pharma’s Application to National Medical Products Administration (NMPA) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (VVC)
13 Sep, 2021 FinancialContent

Submission is part of the Hansoh Pharma licensing agreement and strategic partnership to research, develop and commercialize ibrexafungerp in the Greater China region

SCYNEXIS to Participate in Upcoming Investor Conferences
08 Sep, 2021 FinancialContent
SCYNEXIS Reports Second Quarter 2021 Financial Results and Provides Corporate Update
16 Aug, 2021 FinancialContent
Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 77% over the last five years
13 Aug, 2021 Yahoo! Finance

We're definitely into long term investing, but some companies are simply bad investments over any time frame. We don't...

SCYNEXIS, Inc (SCYX) is a NASDAQ Common Stock listed in , ,

970x250